

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT SHARE REPURCHASE**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to announce that it has an intention to repurchase shares of the Company (the “**Shares**”) on the open market (“**Proposed Repurchase**”). The management team of the Company has full confidence in the prospects of the Group, and the Proposed Repurchase reflects the confidence of the Board and the management team in the Company’s long-term business prospects and growth. The Board believes that the Proposed Repurchase will be in the best interests of the Company and the shareholders of the Company (“**Shareholders**”) as a whole.

As of the date of this announcement, the Company has not yet obtained a general mandate to repurchase Shares not exceeding 10% of the total number of issued Shares (the “**Repurchase Mandate**”) pursuant to Rule 10.06 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”). The Company plans to convene an extraordinary general meeting for the Shareholders to consider and approval of the Repurchase Mandate as soon as practicable. The Company will only conduct the Proposed Repurchase upon approval of the Repurchase Mandate and in compliance with the articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, and all applicable laws and regulations to which the Company is subject to.

Shareholders and potential investors should note that the Proposed Repurchase may be done subject to market conditions and at the Board's absolute discretion and upon the Shareholders' approval of the Repurchase Mandate. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
25 November 2025

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.